252 related articles for article (PubMed ID: 28265301)
1. Assessing histone demethylase inhibitors in cells: lessons learned.
Hatch SB; Yapp C; Montenegro RC; Savitsky P; Gamble V; Tumber A; Ruda GF; Bavetsias V; Fedorov O; Atrash B; Raynaud F; Lanigan R; Carmichael L; Tomlin K; Burke R; Westaway SM; Brown JA; Prinjha RK; Martinez ED; Oppermann U; Schofield CJ; Bountra C; Kawamura A; Blagg J; Brennan PE; Rossanese O; Müller S
Epigenetics Chromatin; 2017; 10():9. PubMed ID: 28265301
[TBL] [Abstract][Full Text] [Related]
2. Deferiprone: Pan-selective Histone Lysine Demethylase Inhibition Activity and Structure Activity Relationship Study.
Khodaverdian V; Tapadar S; MacDonald IA; Xu Y; Ho PY; Bridges A; Rajpurohit P; Sanghani BA; Fan Y; Thangaraju M; Hathaway NA; Oyelere AK
Sci Rep; 2019 Mar; 9(1):4802. PubMed ID: 30886160
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of both the
Bonnici J; Tumber A; Kawamura A; Schofield CJ
Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685975
[TBL] [Abstract][Full Text] [Related]
4. Studies on the catalytic domains of multiple JmjC oxygenases using peptide substrates.
Williams ST; Walport LJ; Hopkinson RJ; Madden SK; Chowdhury R; Schofield CJ; Kawamura A
Epigenetics; 2014 Dec; 9(12):1596-603. PubMed ID: 25625844
[TBL] [Abstract][Full Text] [Related]
5. Recent developments in catalysis and inhibition of the Jumonji histone demethylases.
Sarah L; Fujimori DG
Curr Opin Struct Biol; 2023 Dec; 83():102707. PubMed ID: 37832177
[TBL] [Abstract][Full Text] [Related]
6. Targeting histone lysine demethylases - progress, challenges, and the future.
Thinnes CC; England KS; Kawamura A; Chowdhury R; Schofield CJ; Hopkinson RJ
Biochim Biophys Acta; 2014 Dec; 1839(12):1416-32. PubMed ID: 24859458
[TBL] [Abstract][Full Text] [Related]
7. Lysine Demethylation in Pathogenesis.
Cao J; Yan Q
Adv Exp Med Biol; 2023; 1433():1-14. PubMed ID: 37751133
[TBL] [Abstract][Full Text] [Related]
8. Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy.
Zhang L; Chen Y; Li Z; Lin C; Zhang T; Wang G
Drug Discov Today; 2023 May; 28(5):103519. PubMed ID: 36754142
[TBL] [Abstract][Full Text] [Related]
9. Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
Rotili D; Tomassi S; Conte M; Benedetti R; Tortorici M; Ciossani G; Valente S; Marrocco B; Labella D; Novellino E; Mattevi A; Altucci L; Tumber A; Yapp C; King ON; Hopkinson RJ; Kawamura A; Schofield CJ; Mai A
J Med Chem; 2014 Jan; 57(1):42-55. PubMed ID: 24325601
[TBL] [Abstract][Full Text] [Related]
10. Targeting histone demethylases as a potential cancer therapy (Review).
Diao W; Zheng J; Li Y; Wang J; Xu S
Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35801593
[TBL] [Abstract][Full Text] [Related]
11. A scintillation proximity assay for histone demethylases.
Yu W; Eram MS; Hajian T; Szykowska A; Burgess-Brown N; Vedadi M; Brown PJ
Anal Biochem; 2014 Oct; 463():54-60. PubMed ID: 25010373
[TBL] [Abstract][Full Text] [Related]
12. The catalytic domains of all human KDM5 JmjC demethylases catalyse N-methyl arginine demethylation.
Bonnici J; Oueini R; Salah E; Johansson C; Schofield CJ; Kawamura A
FEBS Lett; 2023 Apr; 597(7):933-946. PubMed ID: 36700827
[TBL] [Abstract][Full Text] [Related]
13. Quantitative high-throughput screening identifies 8-hydroxyquinolines as cell-active histone demethylase inhibitors.
King ON; Li XS; Sakurai M; Kawamura A; Rose NR; Ng SS; Quinn AM; Rai G; Mott BT; Beswick P; Klose RJ; Oppermann U; Jadhav A; Heightman TD; Maloney DJ; Schofield CJ; Simeonov A
PLoS One; 2010 Nov; 5(11):e15535. PubMed ID: 21124847
[TBL] [Abstract][Full Text] [Related]
14. Cancer-associated 2-oxoglutarate analogues modify histone methylation by inhibiting histone lysine demethylases.
Laukka T; Myllykoski M; Looper RE; Koivunen P
J Mol Biol; 2018 Sep; 430(18 Pt B):3081-3092. PubMed ID: 29981745
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic and structural studies of KDM-catalysed demethylation of histone 1 isotype 4 at lysine 26.
Walport LJ; Hopkinson RJ; Chowdhury R; Zhang Y; Bonnici J; Schiller R; Kawamura A; Schofield CJ
FEBS Lett; 2018 Oct; 592(19):3264-3273. PubMed ID: 30156264
[TBL] [Abstract][Full Text] [Related]
16. Chemoprobe-based assays of histone lysine demethylase 1A target occupation enable
Mascaró C; Ortega A; Carceller E; Ruiz Rodriguez R; Ciceri F; Lunardi S; Yu L; Hilbert M; Maes T
J Biol Chem; 2019 May; 294(20):8311-8322. PubMed ID: 30804215
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15.
Duan L; Perez RE; Calhoun S; Maki CG
Cancer Biol Ther; 2022 Dec; 23(1):65-75. PubMed ID: 35100078
[TBL] [Abstract][Full Text] [Related]
18. Recent Progress in Histone Demethylase Inhibitors.
McAllister TE; England KS; Hopkinson RJ; Brennan PE; Kawamura A; Schofield CJ
J Med Chem; 2016 Feb; 59(4):1308-29. PubMed ID: 26710088
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Enzyme Assays for JmjC-Domain-Containing Lysine Histone Demethylases (JmjC-KDMs).
Tarhonskaya H; Tumber A; Kawamura A; Schofield CJ
Curr Protoc Pharmacol; 2018 Mar; 80(1):3.15.1-3.15.12. PubMed ID: 30040204
[TBL] [Abstract][Full Text] [Related]
20. Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases.
Wang Z; Patel DJ
Q Rev Biophys; 2013 Nov; 46(4):349-73. PubMed ID: 23991894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
